Comments on: Fangda advises Genrix Bio in reaching license agreement with Cullinan Therapeutics on BCMA x CD3 Bispecific Antibody for ex-Greater China Territory

Comments on: Fangda advises Genrix Bio in reaching license agreement with Cullinan Therapeutics on BCMA x CD3 Bispecific Antibody for ex-Greater China Territory /press-release/fangda-genrix-bio-cullinan-therapeutics-bcma-x-cd3/ Wed, 02 Jul 2025 08:58:28 +0000 hourly 1